Year 2020 / Volume 112 / Number 10
Editorial
Autoimmune hepatitis, primary sclerosing cholangitis, and inflammatory bowel disease. Sequential overlap syndrome: a twist to the mosaic of autoimmunity

745-747

DOI: 10.17235/reed.2020.7512/2020

Pilar López Serrano, Juan Turnes Vázquez,

Abstract
Autoimmune liver diseases can overlap resulting in a new entity, phenotypically different from those pathologies that converge, and that demonstrates the complexity of our immune system. Sequential overlap syndrome is the consecutive presentation, separated by a variable period of time, of two liver autoimmune diseases, mostly autoimmune hepatitis and primary biliary cholangitis. This syndrome constitutes a challenge both in its diagnosis and in its treatment given the exceptional nature of its presentation. The theory of a mosaic of autoimmunity is proposed to describe this phenomenon.
Share Button
New comment
Comments
No comments for this article
References
1. Czaja AJ. Diagnosis and management of the overlap syndromes of autoimmune hepatitis. Can J Gastroenterol. 2013; 27: 417–423. doi: 10.1155/2013/198070.
2. Abdalian R, Dhar P, Jhaveri K et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology. 2008;47:949. doi:10.1002/hep.22073.
3. Tsaitas C, Semertzidou A, Sinakos E. Update on inflammatory bowel disease in patients with primary sclerosing cholangitis. World J Hepatol. 2014;6:178-187. doi:10.4254/wjh.v6.i4.178.
4. Abdo AA, Bain VG, Kichian K et al. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: A sequential syndrome. Hepatology 2002; 36:1393. https://doi.org/10.1053/jhep.2002.37200.
5. Efe C, Ozaslan E, Heurgué-Berlot A, et al. Sequential presentation of primary biliary cirrhosis and autoimmune hepatitis. Eur J Gastroenterol Hepatol. 2014;26:532-537. doi:10.1097/MEG.0000000000000075.
6. Keskin O, Idilman R. Sequential development of acute autoimmune hepatitis may lead to a serious clinical picture in primary biliary cirrhosis. Eur J Gastroenterol Hepatol. 2015;27(10):1228-1229. doi:10.1097/MEG.0000000000000417.
7. Pinto C, Lagos I, Brahm J. Sequential overlap syndrome: Clinical Characteristics of 10 patients. XXV Annual Meeting of The Latin American Association for the Study of the Liver . República Dominicana. September 2018. Annal of hepatol.2018; 17:1123-1124.
8. Domschke W, Klein R, Terracciano LM, et al. Sequential occurrence of primary sclerosing cholangitis and autoimmune hepatitis type III in a patient with ulcerative colitis: a follow up study over 14 years. Liver. 2000;20(4):340-345. doi:10.1034/j.1600-0676.2000.020004340.x.
9. Nuñez P, Sedano R, Quera R et al. Síndrome de Superposición Autoinmune Secuencial (Hepatitis Autoinmune/ Colangitis Esclerosante Primaria) y Enfermedad Inflamatoria Intestinal: A propósito de 3 casos clínicos. Rev Esp Enferm Dig 2020;112(9):xxx-xxx.
10. Boberg KM, Chapman RW, Hirschfield GM, et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol. 2011;54(2):374-385. doi:10.1016/j.jhep.2010.09.002.
11. Boberg KM, Chapman RW, Hirschfield GM, et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol. 2011;54(2):374-385. doi:10.1016/j.jhep.2010.09.002
12. Sarfaraz S, Anis S. Multiple Autoimmune Syndrome: An Unusual Combination of Autoimmune Disorders (in press). Rev Recent Clin Trials. doi:10.2174/1574887115666200621184110.
13. de Vries AB, Janse M, Blokzijl H et al. Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis. World J Gastroenterol. 2015;21(6):1956-1971. doi:10.3748/wjg.v21.i6.1956.
14. Palmela C, Peerani F, Castaneda D et al. Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Review of the Phenotype and Associated Specific Features. Gut Liver. 2018;12(1):17-29. doi:10.5009/gnl16510.
15. Núñez F P, Quera P R, Gomollón F. Primary sclerosing cholangitis and inflammatory bowel disease: Intestine-liver interrelation. Colangitis esclerosante primaria y enfermedad inflamatoria intestinal: interrelación intestino-hígado. Gastroenterol Hepatol. 2019;42:316-325. doi:10.1016/j.gastrohep.2019.02.004.
16. de Krijger M, Wildenberg ME, de Jonge WJ et al. Return to sender: Lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis. J Hepatol. 2019;71:603-615. doi:10.1016/j.jhep.2019.05.006.
17. Danese S, Semeraro S, Papa A et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol. 2005;11(46):7227-7236. doi:10.3748/wjg.v11.i46.7227.
18. Lazaridis KN, LaRusso NF. Primary Sclerosing Cholangitis. N Engl J Med. 2016;375:1161-1170. doi:10.1056/NEJMra1506330.
19. Trivedi PJ, Chapman RW. PSC, AIH and overlap syndrome in inflammatory bowel disease. Clin Res Hepatol Gastroenterol. 2012;36:420-436. doi:10.1016/j.clinre.2011.10.007.
20. Lunder AK, Hov JR, Borthne A et al. Prevalence of Sclerosing Cholangitis Detected by Magnetic Resonance Cholangiography in Patients With Long-term Inflammatory Bowel Disease. Gastroenterology. 2016;151:660-669.e4. doi:10.1053/j.gastro.2016.06.021.
21. Belle A, Laurent V, Pouillon L et al. Systematic screening for primary sclerosing cholangitis with magnetic resonance cholangiography in inflammatory bowel disease. Dig Liver Dis. 2018;50:1012-1018. doi:10.1016/j.dld.2018.06.024.
22. Eksteen B, Heatherington J, Oshiomogo J et al. Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (PSC) in Individuals with Inflammatory Bowel Disease. J Hepatol 64 (2016) S199. DOI:https://doi.org/10.1016/S0016-5085(16)34283-4.
23. Caron B, Peyrin-Biroulet L, Pariente B et al. Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort Study. J Crohns Colitis. 2019;13(10):1239-1247. doi:10.1093/ecco-jcc/jjz088.
24. Lynch KD, Chapman RW, Keshav S et al. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2020;18(1):179-187.e6. doi:10.1016/j.cgh.2019.05.013.
25. Christensen B, Micic D, Gibson PR et al. Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Aliment Pharmacol Ther. 2018;47(6):753-762. doi:10.1111/apt.14525
Related articles

Letter

Autoimmune hepatitis after SARS-C¬¬oV-2 vaccination

DOI: 10.17235/reed.2023.9579/2023

Letter

Hepatosplenic T-cell lymphoma and inflammatory bowel disease

DOI: 10.17235/reed.2023.9472/2023

Letter

SARS-CoV-2 vaccine, a new autoimmune hepatitis trigger?

DOI: 10.17235/reed.2022.8820/2022

Review

Clinical settings with tofacitinib in ulcerative colitis

DOI: 10.17235/reed.2022.8660/2022

Letter

Anal neoplasia and perianal Crohn’s disease: myth or reality?

DOI: 10.17235/reed.2021.8317/2021

Letter

Apoptotic colopathy as a manifestation of Good’s syndrome

DOI: 10.17235/reed.2021.8297/2021

Editorial

Cases of liver disease lost in the health system: a call to action

DOI: 10.17235/reed.2021.8316/2021

Original

Radon exposure and inflammatory bowel disease in a radon prone area

DOI: 10.17235/reed.2021.8239/2021

Letter

Autoimmune hepatitis triggered by COVID-19

DOI: 10.17235/reed.2021.8045/2021

Review

Inflammatory bowel disease and solid organ transplantation

DOI: 10.17235/reed.2020.7361/2020

Letter

Balanced by iron. Hereditary hemochromatosis and celiac disease

DOI: 10.17235/reed.2020.7269/2020

Letter

Acute hepatitis due to olmesartan: an uncommon entity

DOI: 10.17235/reed.2020.7236/2020

Editorial

Is celiac disease really associated with inflammatory bowel disease?

DOI: 10.17235/reed.2019.6779/2019

Original

Megacolon in inflammatory bowel disease: response to infliximab

DOI: 10.17235/reed.2020.6394/2019

Letter

Fungal cholangitis of the hepatobiliary tract: a case report

DOI: 10.17235/reed.2019.6258/2019

Editorial

Diet in the etiology of inflammatory bowel disease

DOI: 10.17235/reed.2018.6119/2018

Case Report

Serrated Lesions in patients with Inflammatory Bowel Disease.

DOI: 10.17235/reed.2019.5910/2018

Editorial

Online social networks and inflammatory bowel disease

DOI: 10.17235/reed.2018.5496/2018

Letter to the Editor

Autoimmune hepatitis as a complication of common variable immunodeficiency

DOI: 10.17235/reed.2018.5280/2017

Letter to the Editor

Idiopathic portal hypertension with regard to thiopurine treatment

DOI: 10.17235/reed.2018.5256/2017

Editorial

Specialist care in the management of inflammatory bowel disease

DOI: 10.17235/reed.2016.4628/2016

Case Report

The clinical extremes of autoimmune cholangitis

DOI: 10.17235/reed.2017.4167/2015

Citation tools
López Serrano P, Turnes Vázquez J. Autoimmune hepatitis, primary sclerosing cholangitis, and inflammatory bowel disease. Sequential overlap syndrome: a twist to the mosaic of autoimmunity. 7512/2020


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1353 visits.
This article has been downloaded 320 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 08/09/2020

Accepted: 10/09/2020

Online First: 21/09/2020

Published: 07/10/2020

Article Online First time: 13 days

Article editing time: 29 days


Share
This article has been rated by 2 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology